Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them
- PMID: 33215260
- DOI: 10.1007/s00253-020-11012-0
Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them
Abstract
Chimeric virus-like particles (VLPs) were developed as a candidate for allergen-specific immunotherapy. In this study, hepatitis B core antigen (HBcAg) that genetically fused to Chenopodium album polcalcin (Che a 3)-derived peptide was expressed in E. coli BL21, purified, and VLP formation was evaluated using native agarose gel electrophoresis (NAGE) and transmission electron microscopy (TEM). Chimeric HBc VLPs were characterized in terms of their reactivity to IgE, the induction of blocking IgG and allergen-specific IgE, basophil-activating capacity, and Th1-type immune responses. Results from IgE reactivity and basophil activation test showed that chimeric HBc VLPs lack IgE-binding capacity and basophil degranulation activity. Although chimeric HBc VLPs induced the highest level of efficient polcalcin-specific IgG antibody in comparison to those induced by recombinant Che a 3 (rChe a 3) mixed either with HBc VLPs or alum, they triggered the lowest level of polcalcin-specific IgE in mice following immunization. Furthermore, in comparison to the other antigens, chimeric HBc VLPs produced a polcalcin-specific Th1 cell response. Taken together, genetically fusion of allergen derivatives to HBc VLPs, in comparison to a mix of them, may be a more effective way to induce appropriate immune responses in allergen-specific immunotherapy. KEY POINTS: • The insertion of allergen-derived peptide into major insertion region (MIR) of hepatitis B virus core (HBc) antigen resulted in nanoparticles displaying allergen-derived peptide upon its expression in prokaryotic host. • The resultant VLPs (chimeric HBc VLPs) did not exhibit IgE reactivity with allergic patients' sera and were not able to degranulate basophils. • Chimeric HBc VLPs dramatically improved protective IgG antibody response compared with those induced by allergen mixed either with HBc VLPs or alum. • Chimeric HBc VLPs induced Th1 responses that were counterparts of Th2 responses (allergic). • Chimeric HBc VLPs increased IgG2a/ IgG1 ratio and the level of IFN-γ compared to those induced by allergen mixed with either HBc VLPs or alum. Graphical Abstract.
Keywords: Chenopodium album polcalcin; Chimeric viral-like particle; Vaccine design; Virus-like particle.
Similar articles
-
Rational Design of Hypoallergenic Vaccines: Blocking IgE-binding to Polcalcin Using Allergen-specific IgG Antibodies.Iran J Allergy Asthma Immunol. 2020 Jun 23;19(3):276-288. doi: 10.18502/ijaai.v19i3.3455. Iran J Allergy Asthma Immunol. 2020. PMID: 32615661
-
Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo.Cell Immunol. 2007 May;247(1):18-27. doi: 10.1016/j.cellimm.2007.07.003. Epub 2007 Aug 20. Cell Immunol. 2007. PMID: 17707782
-
A novel HBc-S230 protein chimeric VLPs induced robust immune responses against SARS-CoV-2.Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113362. doi: 10.1016/j.intimp.2024.113362. Epub 2024 Oct 18. Int Immunopharmacol. 2024. PMID: 39426233
-
Deviation of the allergic IgE to an IgG response by gene immunotherapy.Int Rev Immunol. 1999;18(3):271-89. doi: 10.3109/08830189909043030. Int Rev Immunol. 1999. PMID: 10614729 Review.
-
Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.J Biotechnol. 1996 Jan 26;44(1-3):91-6. doi: 10.1016/0168-1656(95)00118-2. J Biotechnol. 1996. PMID: 8717391 Review.
Cited by
-
Can Physicochemical Properties Alter the Potency of Aeroallergens? Part 2 - Impact of Physicochemical Properties.Curr Allergy Asthma Rep. 2024 Nov;24(11):609-617. doi: 10.1007/s11882-024-01173-7. Epub 2024 Sep 20. Curr Allergy Asthma Rep. 2024. PMID: 39302572 Free PMC article. Review.
-
Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.Microb Cell Fact. 2023 Feb 25;22(1):39. doi: 10.1186/s12934-023-02043-z. Microb Cell Fact. 2023. PMID: 36841778 Free PMC article.
-
Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.Int J Mol Sci. 2024 Jul 6;25(13):7429. doi: 10.3390/ijms25137429. Int J Mol Sci. 2024. PMID: 39000536 Free PMC article. Review.
-
Virus-like particle vaccinology, from bench to bedside.Cell Mol Immunol. 2022 Sep;19(9):993-1011. doi: 10.1038/s41423-022-00897-8. Epub 2022 Aug 12. Cell Mol Immunol. 2022. PMID: 35962190 Free PMC article. Review.
References
-
- Ai C, Zhang Q, Ding J, Ren C, Wang G, Liu X, Tian F, Zhao J, Zhang H, Chen YQ, Chen W (2015) Suppression of dust mite allergy by mucosal delivery of a hypoallergenic derivative in a mouse model. Appl Microbiol Biotechnol 99(10):4309–4319 - PubMed
-
- Alexander C, Tarzi M, Larche M, Kay A (2005) The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 60(10):1269–1274 - PubMed
-
- Anzaghe M, Schülke S, Scheurer S (2018) Virus-like particles as carrier systems to enhance immunomodulation in allergen immunotherapy. Curr Allergy Asthma Rep 18(12):71 - PubMed
-
- Arora U, Tyagi P, Swaminathan S, Khanna N (2012) Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. J Nanobiotechnol 10(1):30
-
- Bannon GA, Cockrell G, Connaughton C, West CM, Helm R, Stanley JS, King N, Rabjohn P, Sampson HA, Burks AW (2001) Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 124(1-3):70–72 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources